Takeda said it plans to appeal an $885 million jury verdict in a pay-for-delay antitrust case. The lawsuit was brought by pharmacies and wholesalers that alleged Takeda delayed generic competition for a gastrointestinal drug, forcing customers to pay more. In its statement, Takeda argued the trial included evidentiary and legal errors. The planned appeal keeps the dispute in focus for settlements, precedent-setting questions, and how antitrust risk shapes patent and exclusivity strategies across specialty pharmaceuticals. For the broader generics and branded pipeline ecosystem, the case underscores that large damages awards can still arise even amid ongoing legal complexity around patent litigation and regulatory exclusivity timelines.